As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global expansion with Cartistem, its allogeneic human umbilical cord blood-derived ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...